STIM - Neuronetics, Inc Stock Price, Fair Value and News

$1.06+0.05 (+4.95%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

STIM Price Action

Last 7 days

Last 30 days

34.7%

Last 90 days

-46.0%

Trailing 12 Months

-6.5%

STIM RSI Chart

STIM Valuation

Market Cap

30.6M

Price/Earnings (Trailing)

-0.94

Price/Sales (Trailing)

0.42

Price/Free Cashflow

-1.23

STIM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

STIM Fundamentals

STIM Revenue

Revenue (TTM)

72.1M

Rev. Growth (Yr)

-6.59%

Rev. Growth (Qtr)

-5.55%

STIM Earnings

Earnings (TTM)

-32.5M

Earnings Growth (Yr)

-100.61%

Earnings Growth (Qtr)

-24.88%

STIM Profitability

Operating Margin

82.73%

Return on Equity

-167.51%

Return on Assets

-33.54%

Free Cashflow Yield

-81.55%

STIM Investor Care

Shares Dilution (1Y)

4.93%

Diluted EPS (TTM)

-1.1

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	73.2M	72.1M	0	0
2023	66.6M	67.8M	69.2M	71.3M
2022	57.2M	59.3M	62.0M	65.2M
2021	50.1M	54.5M	55.9M	55.3M
2020	61.4M	54.6M	51.0M	49.2M
2019	55.4M	58.7M	60.9M	62.7M
2018	43.1M	46.0M	49.2M	52.8M
2017	35.8M	37.3M	38.9M	40.4M
2016	0	0	0	34.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About Neuronetics, Inc

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

CEO	Mr. Keith J. Sullivan
WEBSITE	https://neurostar.com
SECTOR	Healthcare
INDUSTRY	Diagnostics & Research
EMPLOYEES	209

Neuronetics, Inc Frequently Asked Questions

What is the ticker symbol for Neuronetics, Inc? What does STIM stand for in stocks?

STIM is the stock ticker symbol of Neuronetics, Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Neuronetics, Inc (STIM)?

As of Tue Oct 29 2024, market cap of Neuronetics, Inc is 30.6 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of STIM stock?

You can check STIM's fair value in chart for subscribers.

Is Neuronetics, Inc a good stock to buy?

The fair value guage provides a quick view whether STIM is over valued or under valued. Whether Neuronetics, Inc is cheap or expensive depends on the assumptions which impact Neuronetics, Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for STIM.

What is Neuronetics, Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Oct 29 2024, STIM's PE ratio (Price to Earnings) is -0.94 and Price to Sales (PS) ratio is 0.42. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. STIM PE ratio will change depending on the future growth rate expectations of investors.